


FOURTH
EDITION

Applied Pharmacokinetics & Pharmacodynamics

Principles of Therapeutic Drug Monitoring

Michael E. Burton
Leslie M. Shaw
Jerome J. Schentag
William E. Evans



LIPPINCOTT WILLIAMS & WILKINS

Contents

Dedication and Acknowledgment v

Preface vii

Contributing Authors ix

Editorial Review Board xiii

PART I: BASIC CONCEPTS AND PRINCIPLES 1

1 General Principles of Clinical Pharmacokinetics 3

William E. Evans

2 Guidelines for Collection and Analysis of Pharmacokinetic Data 8

William J. Jusko

3 Critical Evaluation of Methods for Therapeutic Drug Monitoring 30

Victor W. Armstrong and Michael Oellerich

4 Analysis of Pharmacokinetic Data for Individualizing Drug Dosage Regimens 40

John H. Rodman, David Z. D'Argenio, and Carl C. Peck

5 Pharmacodynamics 60

Richard L. Lalonde

6 Influence of Protein Binding and Use of Unbound (Free) Drug Concentrations 82

Janis J. MacKichan

7 Drug Metabolism, Transport, and the Influence of Hepatic Disease 121

Angela D.M. Kashuba, Joohyun J. Park, Adam M. Persky, and Kim L.R. Brouwer

8 Application of Pharmacogenetic Principles to Clinical Pharmacology 165

Mark W. Linder, William E. Evans, and Howard L. McLeod

9 Influence of Renal Function and Dialysis on Drug Disposition 187

Gary R. Matzke and Thomas J. Comstock

10 Special Pharmacokinetic and Pharmacodynamic Considerations in Children 213

Holly D. Maples, Laura P. James, and Cindy D. Stowe

11 Special Pharmacokinetic Considerations in the Obese 231

Robert A. Blouin and Mary H.H. Ensom

12 Dietary Influences on Drug Disposition 242

Mary H.H. Ensom and Robert A. Blouin

PART II: MONITORED DRUGS 257

13 Asthma Management 259

Glenn J. Whelan and Stanley J. Szefer

14 Aminoglycosides 285

Jerome J. Schentag, Alison K. Meagher, and Roger W. Jelliffe

15 Vancomycin 328

Pamela A. Moise-Broder

16 Microbiologic, Clinical, and Economic Outcomes of Dual Individualized Dosing of Antimicrobial Agents 341

Joseph A. Paladino and Jerome J. Schentag

17 Antivirals for HIV 354

Craig R. Rayner, Michael J. Dooley, and Roger L. Nation

18 Digoxin 410

Jerome J. Schentag, Anthony J. Bang, and Jennifer L. Kozinski-Tober

- 19 Clinical Pharmacokinetics of Oral Antiarrhythmic Drugs 440**
Jerry L. Bauman, Harumi Takahashi, and James H. Fischer
- 20 Phenytoin 463**
Michael E. Winter and Thomas N. Tozer
- 21 Antiepileptic Drugs 491**
William R. Garnett, Gail D. Anderson, and Rebecca J. Collins
- 22 Cyclosporine 512**
Atholl Johnston and David W. Holt
- 23 Tacrolimus 529**
Uwe Christians, Taveesak Pokaiyavanichkul, and Laurence Chan
- 24 Mycophenolic Acid 563**
Arthur Nawrocki, Magdalena Korecka, Sandra Solari, Juseop Kang, and Leslie M. Shaw
- 25 Sirolimus 595**
Barry D. Kahan and Kimberly L. Napoli
- 26 Anticancer Agents 617**
William P. Petros and William E. Evans
- 27 Heparin — UFH and LMWH 637**
Keith A. Rodvold, Sharon M. Erdman, Kelly A. Sprandel, Robert J. Cipolle, and Eleanor S. Pollak
- 28 Warfarin 715**
Stuart T. Haines, Thomas Dowling, and R. Donald Harvey, III
- 29 Nonsteroidal Anti-Inflammatory Drugs and Coxibs 752**
Tilo Grosser
- 30 Cyclic Antidepressants 781**
C. Lindsay DeVane
- 31 Lithium 798**
Tawny L. Bettinger and M. Lynn Crismon
- 32 Antipsychotics 813**
James M. Perel and Michael W. Jann
- Appendix: A Critical Assessment of the Outcomes of Therapeutic Drug Monitoring 839**
Mary H.H. Ensom and Michael E. Burton
- Index 849**